Historically, cancer treatment has relied on a one-size-fits-all approach where drugs and other therapies designed to target large groups of individuals are prescribed based on population parameters, but not on the individual patient’s likelihood of positive response. Precision oncology is here to change that.
Historically, cancer treatment has relied on a one-size-fits-all approach where drugs and other therapies designed to target large groups of individuals are prescribed based on population parameters, but not on the individual patient’s likelihood of positive response. Precision oncology is here to change that.
We're developing a proprietary Drug Activity Ranking to provide oncologists with actionable patient-derived data to aid them in the therapy selection process.
We're leveraging deep scientific expertise in screening technologies combined with the power of high-throughput flow cytometry to better understand how patients may respond to drugs, before they're actually prescribed.
OncoPrecision's Team is driven by a strong conviction and belief that each patient is unique and therefore requires tailored care.
In this work we developed a flow-cytometry-based co-culture screening technology for drug discovery, and we used to explore a public kinase inhibitor set.
In this work we used our flow-cytometry-based co-culture screening technology to screen a collection of 50 plants species from South America in a wide dose-response scheme.
In this work we performed In Silico screenings to identifty phosphor regulatory sites of the EMT factor ZEB1 and validated PKCα as a novel partner capable of modulating its premetastatic properties.
In this work we perform studies of correlations of drug sensitivity of a cell line database with transcriptomic classes of cancer cells derived from a commercial breast cancer signature.
